A scalable, non-invasive platform for longitudinal reproductive health monitoring.

Cervical cancer, endometriosis, and PCOS are routinely under-diagnosed. The clinical samples that could detect them — menstrual blood, in particular — are produced by billions of women every month and thrown away. Existing diagnostics are invasive, painful, or expensive enough to gate access for the people who need them most.

Sensible is engineered as a familiar consumer product — the menstrual pad — with embedded diagnostic capability. Sample collection is passive and pain-free. Analysis happens without a lab visit, returning clinically-actionable data to the user and, with consent, to a downstream care pathway.

Through strategic engagement with GHF Ventures, Sensible sharpened its commercial thesis — evolving from a single-indication diagnostic model into a scalable, non-invasive platform for longitudinal reproductive-health monitoring. The pivot is the story: the original case was good, the platform thesis is bigger, and the room helped surface it.

Nandini Kanthi (CEO & Co-Founder), Juliet Wu, and Ishita Bafna lead the team. The founding cohort came up through Lemelson-MIT, USA Today, and UNC Gillings — building the product in public for years before the 2025 Venture Forum.

Recognition that mattered, in order — culminating in the $25,000 Venture Forum Prize and the platform pivot that followed.

Sensible was awarded the $25,000 Venture Forum Prize, funded by WestBridge Capital — the first prize of its kind within the GHF platform. (For the 2026 cycle, the headline check scales to a $100K–$10M direct investment from WestBridge Capital and Hitachi Ventures on standard SAFE terms.)

Sensible is actively building clinical-validation partnerships, distribution agreements with women’s-health networks, and a follow-on round of capital. Introductions and customer pilots welcomed via the GHF Ventures network.